David Day and a lifetime of missed moments

David Day and a lifetime of missed moments

8 June 2018

“I couldn’t eat. Barely slept. I was the one to tell Dave it was all over. All Dave said was ‘my poor, poor babies’.”  Jenny, David’s wife.

When David lost his life last year, he was 33, with three daughters under six.

David Day was one of the 20% of people with advanced melanoma have primary resistance to new drugs with ‘super progression' and we need to find out why. 

The greatest challenge our clinicians currently face in treating melanoma is ‘super progression’.

Amid all our success stories, there is still a group of people with advanced melanoma for whom absolutely nothing works. About 20% of patients our medical oncologists see with advanced melanoma fall into this category.

Super progressors do not respond to existing treatments. Within a few short months, their disease progresses aggressively and relentlessly and we cannot save them.

David Day, was one such patient —a lovely young father with a wonderful family — who died last year.

The most agonising thing about patients like David is that at present, we just don’t know why they super progress.

Dr Inês Silva was part of the clinical team which treated David Day. She was studying at MIA as a Medical Oncology Fellow from Portugal. David had such a profound impact on Inês, that on completion of her Fellowship, she decided to stay on at MIA as a Research Scientist in an all-out attempt to find answers for super progressors.

Inês and the MIA research team collected blood and melanoma tissue samples from David during his treatment. They also collected similar samples from other advanced melanoma patients who have not responded to immunotherapy.

By studying the genomic profile and protein expression in each of these patients’ tumours, Ines and the MIA research team hope to understand why each drug failed to work, paving the way for new, and potentially life-saving therapies.

While there is some existing grant funding to cover her salary, a dedicated Research Scientist like Inês can’t do it alone.

We are relying on you and on the support of our donor community to collectively fund this research project including research assistants’ salaries, PhD student scholarship top-ups, equipment, and state-of-the-art research technologies such as DNA, RNA and cell sequencing. All are key to understanding and solving primary resistance and super progression.

David was a sweet, humble family man. He was a high-achiever, had forged an exceptional career as a computer engineer for Google and made a loving, happy life raising his three daughters Charlotte, 7, Emma, 5, and Annie, now 1, with his wife Jenny, his childhood sweetheart since Year 9.

Just before Christmas 2016, with Jenny heavily pregnant with little Annie, Dave found a lump under his left arm. He had Stage III melanoma. Half way through his treatment, David found another lump under his arm and a new tumour was discovered on his left hip. His melanoma had progressed to Stage IV.

In March 2017, David and Jenny were referred to Melanoma Institute Australia. He started on a clinical trial and at first, his scans looked promising.

After starting treatment, another painful melanoma appeared on David’s wrist. In the next three months, tumours sprang up in his spleen, lungs, pancreas, bones, under his skin —  with up to 30 more in his liver. Even though immune cells were present, David was super progressing.

As the months passed, David suffered extreme pain, liver damage, rapid weight loss, blurred vision and internal bleeding. The clinical team switched to chemotherapy as a last resort and Annie’s christening was pushed forward.

On 25 August 2017, Jenny had the worst imaginable task of explaining to her soul mate that nothing more could be done for him.

“I was the one to tell him it was over. All he could say was “My poor, poor babies”. My heart ached. I had lost 15kg over the past five months from the stress of the whole situation. My milk dried up and I couldn’t feed Annie. It ate away at me while I put on a brave face for Dave and the kids,” says Jenny.

Jenny has very generously shared her painful story in the hope that it will help raise funds to crack the riddle of super progression. 

Please give today to save someone you know from the ravages of melanoma in the future, and give them what David didn’t have- the opportunity to enjoy a lifetime of special moments with their loved ones.

Donate now

 

Using clinical features to identify patients at high risk for melanoma
10 Nov 2016

Using clinical features to identify patients at high risk for melanoma

Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?

MIA congratulates Professor Georgina Long
09 Nov 2016

Congratulations to Professor Georgina Long

Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).

Tags: more news
Uniting our global researchers for melanoma
28 Oct 2016

Uniting our global researchers for melanoma

The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.

Best practice guidelines for melanoma care go digital
28 Oct 2016

Best practice guidelines for melanoma care go digital

Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.

Awards and honours for our talented researchers
26 Oct 2016

Awards and honours for our talented researchers

Congratulations are in order for two of our talented researchers.

5 Minutes With Prof Richard Scolyer
21 Oct 2016

5 Minutes With Prof Richard Scolyer

Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on. 

Research spotlight: High Risk Clinic
10 Oct 2016

Research spotlight: High Risk Clinic

Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.

Learning from the best in the world
05 Oct 2016

Learning from the best in the world

A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.

Uniting the world for a cure
30 Sep 2016

Uniting the world for a cure

MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients

A Day in the Life of... Michelle Peranec
30 Sep 2016

A Day in the Life of... Michelle Peranec

Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.

Wildfire Award helps ignite new melanoma research
08 Sep 2016

Wildfire Award helps ignite new melanoma research

Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.

Opinion: Fighting the Resistance
25 Aug 2016

Opinion: Fighting the Resistance

Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.

5 Minutes With A/Prof Jennifer Wargo
11 Aug 2016

5 Minutes With A/Prof Jennifer Wargo

A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.

Dr James Wilmott awarded for outstanding cancer research
06 Aug 2016

Dr James Wilmott awarded for outstanding cancer research

Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.

Community invests in MIA's new trial
19 Jul 2016

Community invests in MIA's new trial

The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial. 

New trial giving options
18 Jul 2016

New trial giving options

We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.

Melanoma research summary from ASCO
07 Jul 2016

Melanoma research summary from ASCO

Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.

Our Privacy Policy has been updated
06 Jul 2016

Updated privacy policy

We value your privacy and want you to be familiar with how we collect, use and disclose your information.

Can cognitive technology assist with melanoma identification?
29 Jun 2016

Can cognitive technology assist with melanoma identification?

Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.

'4 Questions With...' Series
24 Jun 2016

'4 Questions With...' Series

CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.